DGIdb - ZIPRASIDONE Drug Record

ZIPRASIDONE chembl:CHEMBL708 Approved

Alternate Names:

GEODON
CP-88059
ZIPRASIDONE
CP-88059-27
CP-880591
ZIPRASIDONE HYDROCHLORIDE
ZIPRASIDONUM
ZIPRASIDONA
CP-8805927
GEODON®
rxcui:115698
pubchem.compound:60854
chembl:CHEMBL708
drugbank:00246
chemidplus:146939-27-7

Drug Info:

FDA Approval	approved
Drug Class	small molecule
Drug Indications	antipsychotic agent
Drug Class	antipsychotic agents
Year of Approval	2001
Drug Categories	adrenergic alpha-1 receptor antagonists
Drug Categories	adrenergic alpha-antagonists
Drug Categories	adrenergic antagonists
Drug Categories	agents that produce hypertension
Drug Categories	anticholinergic agents
Drug Categories	antidepressive agents
Drug Categories	cytochrome p-450 cyp2d6 inhibitors (weak)
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 substrates (strength unknown)
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	dopamine d2 receptor antagonists
Drug Categories	histamine antagonists
Drug Categories	histamine h1 antagonists
Drug Categories	muscarinic antagonists
Drug Categories	neurotoxic agents
Drug Categories	qtc prolonging agents
Drug Categories	serotonergic drugs shown to increase risk of serotonin syndrome
Drug Categories	serotonin 5-ht1 receptor agonists
Drug Categories	serotonin 5-ht1 receptor antagonists
Drug Categories	serotonin 5-ht2 receptor antagonists
Drug Categories	serotonin receptor agonists
Drug Categories	serotonin receptor antagonists

(4 More Sources)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Andersohn et al., 2010, Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity., J Clin Psychopharmacol
Stahl et al., 2003, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice., J Clin Psychiatry
Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
Seeger et al., 1995, Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity., J. Pharmacol. Exp. Ther.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Kopecek et al., 2005, Ziprasidone-induced galactorrhea: a case report., Neuro Endocrinol. Lett.
Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.
Sprouse et al., 1999, Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation., Neuropsychopharmacology
Wilner et al., 2002, The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery., J Clin Psychopharmacol
Cates ME, 2003, Ziprasidone--not an option for serotonin syndrome., CMAJ
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Wood et al., 2006, Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade., CNS Neurol Disord Drug Targets
Sánchez et al., 2000, In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics., Behav Pharmacol
Arnt, 1995, Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine., Eur. J. Pharmacol.
Schmidt et al., 2001, Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile., Eur. J. Pharmacol.
Newman-Tancredi et al., 2003, Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924., Naunyn Schmiedebergs Arch. Pharmacol.
Rollema et al., 2000, 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex., Biol. Psychiatry
Mansbach et al., Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone., Pharmacol. Biochem. Behav.
Kast et al., 2007, Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone., Bone Marrow Transplant.
Ichikawa et al., 2002, Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism., Brain Res.
Lu et al., 2002, A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics., J Clin Psychiatry
Mamo et al., 2004, A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone., Am J Psychiatry
Stark et al., 2007, Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies., Psychopharmacology (Berl.)
Meltzer, 1995, Role of serotonin in the action of atypical antipsychotic drugs., Clin. Neurosci.
Meltzer, 1999, The role of serotonin in antipsychotic drug action., Neuropsychopharmacology
Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
Thompson AJ et al., 2006, 5-HT3 receptors., Curr Pharm Des
Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
Nelson DL, 2004, 5-HT5 receptors., Curr Drug Targets CNS Neurol Disord

ZIPRASIDONE SLC6A4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
ZIPRASIDONE ADRA2C

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE DRD3

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE DRD4

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE ADRA1A

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Andersohn et al., 2010, Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity., J Clin Psychopharmacol

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE DRD2

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Publications:

Stahl et al., 2003, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice., J Clin Psychiatry

Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry

Seeger et al., 1995, Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity., J. Pharmacol. Exp. Ther.

ZIPRASIDONE HTR1D

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Publications:

Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.

Seeger et al., 1995, Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity., J. Pharmacol. Exp. Ther.

Sprouse et al., 1999, Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation., Neuropsychopharmacology

ZIPRASIDONE HTR2C

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Inverse agonist

Endogenous Drug? False

Direct Interaction? True

Publications:

Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.

Wood et al., 2006, Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade., CNS Neurol Disord Drug Targets

Sánchez et al., 2000, In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics., Behav Pharmacol

ZIPRASIDONE ADRA2A

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
ZIPRASIDONE HTR1E

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Full agonist

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE HRH1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Publications:

Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.

Arnt, 1995, Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine., Eur. J. Pharmacol.

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE HTR6

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
ZIPRASIDONE CHRM4

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE HTR1A

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Publications:

Schmidt et al., 2001, Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile., Eur. J. Pharmacol.

Wilner et al., 2002, The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery., J Clin Psychopharmacol

Stahl et al., 2003, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice., J Clin Psychiatry

ZIPRASIDONE ADRA2B

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE HTR2A

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Publications:

Mansbach et al., Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone., Pharmacol. Biochem. Behav.

Stahl et al., 2003, The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice., J Clin Psychiatry

Kast et al., 2007, Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone., Bone Marrow Transplant.

ZIPRASIDONE HTR7

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Inverse agonist

Publications:

Stark et al., 2007, Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies., Psychopharmacology (Berl.)

Meltzer, 1995, Role of serotonin in the action of atypical antipsychotic drugs., Clin. Neurosci.

Meltzer, 1999, The role of serotonin in antipsychotic drug action., Neuropsychopharmacology

ZIPRASIDONE DRD5

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE HTR1B

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Schmidt et al., 2001, Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile., Eur. J. Pharmacol.

ZIPRASIDONE CHRM1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
ZIPRASIDONE CHRM5

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
ZIPRASIDONE DRD1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE HTR3A

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Thompson AJ et al., 2006, 5-HT3 receptors., Curr Pharm Des

ZIPRASIDONE CHRM2

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
ZIPRASIDONE ADRA1B

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
ZIPRASIDONE CHRM3

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE HTR5A

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Nelson DL, 2004, 5-HT5 receptors., Curr Drug Targets CNS Neurol Disord

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

ZIPRASIDONE CYP3A5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

ZIPRASIDONE MC4R

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull

Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol

Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry

ZIPRASIDONE EIF2AK4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics

ZIPRASIDONE AR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
ZIPRASIDONE CHRNA7

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
ZIPRASIDONE ADRB1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
ZIPRASIDONE RGS4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
ZIPRASIDONE EHMT2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB00246

Version: 5.1.7

Alternate Names:

ZIPRASIDONE DrugBank Drug Name

146939-27-7 CAS Number

Auro-ziprasidone Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories adrenergic alpha-1 receptor antagonists

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov

TEND: ZIPRASIDONE
- Version: 01-August-2011
Alternate Names:

ZIPRASIDONE Primary Drug Name

Drug Info:

Year of Approval 2001

Drug Class antipsychotic agents

Publications:
TdgClinicalTrial: ZIPRASIDONE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antipsychotic agent

Drug Class small molecule

FDA Approval approved

Publications:

PharmGKB: ziprasidone

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry

Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry

GuideToPharmacology: 135651359
- Version: 29-September-2020
Alternate Names:

ZIPRASIDONE GuideToPharmacology Ligand Name

Drug Info:

Publications:
DTC: ZIPRASIDONE
- Version: 02-September-2020
Alternate Names:

CHEMBL708 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Ziprasidone
- Version: 2020.06.01
Alternate Names:

D0R1JV TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL708
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	False

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Antagonist

Specific Action of the Ligand	Full agonist
Endogenous Drug?	False

Specific Action of the Ligand	Inverse agonist
Endogenous Drug?	False
Direct Interaction?	True

Specific Action of the Ligand	Partial agonist
Endogenous Drug?	False

ZIPRASIDONE	DrugBank Drug Name
146939-27-7	CAS Number
Auro-ziprasidone	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	adrenergic alpha-1 receptor antagonists

ZIPRASIDONE Drug Record

ZIPRASIDONE chembl:CHEMBL708 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Andersohn et al., 2010, Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity., J Clin Psychopharmacol Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Antagonist

Interaction Types & Directionality: antagonist (inhibitory) agonist (activating)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Specific Action of the Ligand Inverse agonist Endogenous Drug? False Direct Interaction? True

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: agonist (activating) antagonist (inhibitory)

Interaction Info: Endogenous Drug? False Specific Action of the Ligand Full agonist

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Specific Action of the Ligand Antagonist Endogenous Drug? False

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Partial agonist Endogenous Drug? False

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Antagonist

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Endogenous Drug? False Specific Action of the Ligand Inverse agonist

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: agonist (activating) antagonist (inhibitory)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry Schmidt et al., 2001, Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile., Eur. J. Pharmacol.

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry Thompson AJ et al., 2006, 5-HT3 receptors., Curr Pharm Des

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Nelson DL, 2004, 5-HT5 receptors., Curr Drug Targets CNS Neurol Disord Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Andersohn et al., 2010, Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity., J Clin Psychopharmacol

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Interaction Types & Directionality:

antagonist (inhibitory)

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Inverse agonist

Endogenous Drug? False

Direct Interaction? True

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Full agonist

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Inverse agonist

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Schmidt et al., 2001, Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile., Eur. J. Pharmacol.

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Thompson AJ et al., 2006, 5-HT3 receptors., Curr Pharm Des

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Nelson DL, 2004, 5-HT5 receptors., Curr Drug Targets CNS Neurol Disord

Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry

Interaction Types & Directionality:

n/a

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Alternate Names:

ZIPRASIDONE DrugBank Drug Name

146939-27-7 CAS Number

Auro-ziprasidone Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories adrenergic alpha-1 receptor antagonists